Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy

BACKGROUND: Drug combinations of the proteasome inhibitor bortezomib with cytotoxic chemotherapy are currently evaluated in phase 2 and 3 trials for the treatment of paediatric acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL). METHODS: We investigated whether expression ratios of...

Descripción completa

Detalles Bibliográficos
Autores principales: Niewerth, Denise, Kaspers, Gertjan J. L., Jansen, Gerrit, van Meerloo, Johan, Zweegman, Sonja, Jenkins, Gaye, Whitlock, James A., Hunger, Stephen P., Lu, Xiaomin, Alonzo, Todd A., van de Ven, Peter M., Horton, Terzah M., Cloos, Jacqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011854/
https://www.ncbi.nlm.nih.gov/pubmed/27599459
http://dx.doi.org/10.1186/s13045-016-0312-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011854/
https://www.ncbi.nlm.nih.gov/pubmed/27599459
http://dx.doi.org/10.1186/s13045-016-0312-z

Ejemplares similares